The Week’s Edge

The US and Japan spent US$60 billion defending the yen. Half the move was gone in eight days. Here’s why the US-Japan yen intervention is failing.

The ASX enters earnings season near record highs. Here are the valuations, sectors, stocks and global risks that could decide what happens next.

Gold money is rotating out of ASX materials and into ASX healthcare. Why CSL, ResMed and Sonic are worth watching after a 39.6% de-rating.

On Wednesday, the ceasefire died. Missiles hit tankers in the Strait of Hormuz. Washington revoked the waiver that let Iran sell its crude.

Five high-yield ASX dividend stocks, from the beaten-down to the record-breakers. Gross up for franking and the income league runs opposite to the share-price charts.

The 2026 budget scrapped the 50% CGT discount. ASX growth names dropped 8-15% in two weeks while defensive REITs ran. Here is where capital goes next.

There was a big move signalled in the budget this week. It could be just the beginning of a complete overhaul of one of our most crucial industries.
While the country argues…

Three quiet ASX compounders — Biome (BIO), Compumedics (CMP) and Advanced Braking (ABV). One catalyst pending, two just fired. Verdicts, scorecards, and what to watch.

Let me tell you about a chokepoint.
It’s 33 kilometres wide at its narrowest. Two shipping lanes, each barely wider than a football field. Every single day, twenty million barrels…

It’s been a brutal two weeks in the share market.
The US and Israel have picked a fight with Iran in the most brutal of fashions. Bombs, assassinations, and heaps of name calling.